CTLA4 and neoplasm: In a recent report, Snyder et al. [8] showed that tumor mutational load, estimated by WES, was higher in melanoma patients presenting long-term clinical benefit to CTLA-4 blockade when compared to patients with minimal or no clinical benefit.